Scientific studies on a vaccine against norovirus, the top source of gastroenteritis in the U.S., are set to come to an end this year. Takeda Pharmaceutical Co., the most efficient immunization candidate, has developed a vaccine against norovirus.
The shots will keep people protected reducing possibilities of an individual to be infected by this germ down to 5%.
This is very good news as a norovirus vaccine would be a boon to cruise ships, schools and nursing homes struggling to deal with a highly contagious diseases.
A vaccine would be more vital for individuals with a high risk of exposure or weakened immune defenses.
Norovirus, also known as the winter vomiting bug, can be caught from an infected person, contaminated food or water, or by touching contaminated surfaces, according to the CDC. It causes the stomach and intestines to become inflamed, resulting in pain, nausea, diarrhea, and vomiting.
This is very good news as a norovirus vaccine would be a boon to cruise ships, schools and nursing homes struggling to deal with a highly contagious diseases.
A vaccine would be more vital for individuals with a high risk of exposure or weakened immune defenses.
Norovirus, also known as the winter vomiting bug, can be caught from an infected person, contaminated food or water, or by touching contaminated surfaces, according to the CDC. It causes the stomach and intestines to become inflamed, resulting in pain, nausea, diarrhea, and vomiting.
It is more common in the US from November to April.
If approved, Takeda’s norovirus vaccine would be the first to protect people against the germ.
Related Article: Crucial Cruise Ship HACCP Sanitation Internationally Certificated Course required for Crew
If approved, Takeda’s norovirus vaccine would be the first to protect people against the germ.
Related Article: Crucial Cruise Ship HACCP Sanitation Internationally Certificated Course required for Crew
